BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 35931181)

  • 1. Medication-Related Osteonecrosis of the Jaws in the Pediatric Population.
    Neal TW; Schlieve T
    J Oral Maxillofac Surg; 2022 Oct; 80(10):1686-1690. PubMed ID: 35931181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interventions for managing medication-related osteonecrosis of the jaw.
    Beth-Tasdogan NH; Mayer B; Hussein H; Zolk O
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD012432. PubMed ID: 28983908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.
    Owosho AA; Liang STY; Sax AZ; Wu K; Yom SK; Huryn JM; Estilo CL
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2018 May; 125(5):440-445. PubMed ID: 29580668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).
    Fusco V; Campisi G; Bedogni A
    Support Care Cancer; 2022 Sep; 30(9):7047-7051. PubMed ID: 35312858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging antiresorptive medications and their potential implications for dental surgeries.
    Aminoshariae A; Donaldson M; Horan M; Mackey SA; Kulild JC; Baur D
    J Am Dent Assoc; 2022 Jul; 153(7):649-658. PubMed ID: 35277242
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Frequency of Medication-related Osteonecrosis of the Jaw and its Associated Risk Factors.
    Dodson TB
    Oral Maxillofac Surg Clin North Am; 2015 Nov; 27(4):509-16. PubMed ID: 26362367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
    Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
    Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and Risk Factors of Osteonecrosis of the Jaw in Advanced Cancer Patients after Treatment with Zoledronic Acid or Denosumab: A Retrospective Cohort Study.
    Kajizono M; Sada H; Sugiura Y; Soga Y; Kitamura Y; Matsuoka J; Sendo T
    Biol Pharm Bull; 2015; 38(12):1850-5. PubMed ID: 26632176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CT imaging features of antiresorptive agent-related osteonecrosis of the jaw/medication-related osteonecrosis of the jaw.
    Baba A; Goto TK; Ojiri H; Takagiwa M; Hiraga C; Okamura M; Hasegawa S; Okuyama Y; Ogino N; Yamauchi H; Kobashi Y; Yamazoe S; Munetomo Y; Mogami T; Nomura T
    Dentomaxillofac Radiol; 2018 May; 47(4):20170323. PubMed ID: 29365278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of medication-related osteonecrosis of the jaw after dental extractions in patients receiving antiresorptive agents - A retrospective study of 240 patients.
    Coropciuc R; Coopman R; Garip M; Gielen E; Politis C; Van den Wyngaert T; Beuselinck B
    Bone; 2023 May; 170():116722. PubMed ID: 36858337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab.
    Bracchi P; Zecca E; Brunelli C; Miceli R; Tinè G; Maniezzo M; Lo Dico S; Caputo M; Shkodra M; Caraceni AT
    Cancer Med; 2023 Sep; 12(17):18317-18326. PubMed ID: 37559413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dental implants as risk factors for patients with medication-related osteonecrosis of the jaws (MRONJ).
    Pichardo SEC; van der Hee JG; Fiocco M; Appelman-Dijkstra NM; van Merkesteyn JPR
    Br J Oral Maxillofac Surg; 2020 Sep; 58(7):771-776. PubMed ID: 32631756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Both non-surgical dental treatment and extractions increase the risk of medication-related osteonecrosis of the jaw: case-control study.
    McGowan K; Ware RS; Acton C; Ivanovski S; Johnson NW
    Clin Oral Investig; 2019 Nov; 23(11):3967-3975. PubMed ID: 30747305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases.
    Ikesue H; Mouri M; Tomita H; Hirabatake M; Ikemura M; Muroi N; Yamamoto S; Takenobu T; Tomii K; Kawakita M; Katoh H; Ishikawa T; Yasui H; Hashida T
    Support Care Cancer; 2021 Aug; 29(8):4763-4772. PubMed ID: 33527228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?
    Soutome S; Hayashida S; Funahara M; Sakamoto Y; Kojima Y; Yanamoto S; Umeda M
    PLoS One; 2018; 13(7):e0201343. PubMed ID: 30048523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medication-related osteonecrosis of the jaw in a paediatric patient taking denosumab: a case report.
    Innes-Taylor D; Adams V
    Br Dent J; 2024 Mar; 236(6):453-456. PubMed ID: 38519674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of medication-related osteonecrosis of the jaws in metastatic prostate cancer patients.
    Wei LY; Kok SH; Lee YC; Chiu WY; Wang JJ; Cheng SJ; Chang HH; Lee JJ
    Oral Dis; 2022 Jan; 28(1):182-192. PubMed ID: 33254278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases.
    Ikesue H; Doi K; Morimoto M; Hirabatake M; Muroi N; Yamamoto S; Takenobu T; Hashida T
    Cancer Chemother Pharmacol; 2021 Jun; 87(6):871-877. PubMed ID: 33791853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Position paper on medication-related osteonecrosis of the jaw (MRONJ)].
    Svejda B; Muschitz Ch; Gruber R; Brandtner Ch; Svejda Ch; Gasser RW; Santler G; Dimai HP
    Wien Med Wochenschr; 2016 Feb; 166(1-2):68-74. PubMed ID: 26847441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dental pathologies in tumor patients with bone metastases or multiple myeloma scheduled for antiresorptive therapy.
    Laimer J; Hechenberger M; Müller D; Walch B; Kolk A; Schnabl D; Schomaker M; Bruckmoser E
    Future Oncol; 2021 Jul; 17(21):2705-2711. PubMed ID: 33880956
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.